Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Fesoterodine SR Beads-in-Capsule vs Commercial ER
NCT02160158Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fesoterodine in overactive bladder (OAB) (2 cohorts), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time at 48 hours and Maximum Observed Plasma Concentration at 48 hours. Started Jul 2014; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02160158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02160158.